FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the use rasburicase for preparing a drug preparation for treating or preventing cardiac disorders or indirect complications caused by ischemic strokes or reperfusion. Coronary blood flow and contractility in the rats' isolated hearts make 4200±348-4657±215 and 13.3±0.81-15.7±0.7 respectively with uric acid added, 3917±252-4311±260 and 12.27±1.16-14.09±0.86 respectively with no uric acid added.
EFFECT: invention provides normalising the coronary blood flow and the improved contractility.
9 cl, 1 dwg, 6 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BANKING PROCESS | 2006 |
|
RU2440131C2 |
| SOLUTION FOR PERFUSION AND/OR PRESERVATION OF ORGANS AND WAYS OF ITS APPLICATION | 2006 |
|
RU2397641C2 |
| APPLICATION OF KAURAN COMPOUNDS FOR MEDICINES PRODUCTION | 2004 |
|
RU2345761C2 |
| METHOD FOR DIAGNOSING THE CASES OF CHRONIC CARDIAC ISCHEMIA DISEASE | 2001 |
|
RU2200951C2 |
| METHOD FOR REDUCING THE SIZE OF ISCHEMIC-REPERFUSION MYOCARDIAL INJURY WITH THE USE OF QUINACRINE | 2019 |
|
RU2716596C1 |
| METHOD OF PROPHYLAXIS AND TREATMENT OF PATIENT WITH MYOCARDIUM ISCHEMIA IN CORONARY-INVASIVE OPERATIONS | 1999 |
|
RU2146933C1 |
| APPLICATION OF GHRP-6 AS A CARDIOPROTECTIVE AND CARDIORESTORATIVE MEDICINAL PRODUCT FOR LATE TREATMENT | 2019 |
|
RU2779835C1 |
| APPLICATION OF CARIPORIDE FOR DECREASING UNFAVORABLE IMPACT OF MACROLIDE ANTIBIOTICS IN CASE OF CARDIAC ISCHEMIA AND REPERFUSION | 1998 |
|
RU2252754C2 |
| 5-POTASSIUM HYDROXINICOTINATE WITH CARDIOPROTECTIVE ACTIVITY | 2017 |
|
RU2640580C1 |
| N-HYDROXYLSULPHONAMIDE DERIVATIVES AS NOVEL PHYSIOLOGICALLY USEFUL NITROXYL DONORS | 2008 |
|
RU2485097C2 |
